Protagonist Therapeutics, Inc. PTGX · Stock Open Protagonist Therapeutics, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Protagonist Therapeutics, Inc. Analysis (PTGX)
Is Protagonist Therapeutics, Inc. a good investment? Protagonist Therapeutics, Inc. (PTGX) is currently trading at 143.37 USD. Market analysts have a consensus price target of 178.57 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 135.31. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Protagonist Therapeutics, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -0.10.
Investor FAQ
Does Protagonist Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Protagonist Therapeutics, Inc.?
Protagonist Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of 1.03.
Company Profile
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Community Discussion